Biodel (BIOD) jumps 14% in premarket trading.
The company has inked a long-term supply deal with Becton, Dickinson (BDX) for exclusive rights to the BD Uniject SCF Disposable Auto-Disable Injection System.
BIOD will leverage the device to serve the "glucagon rescue treatment market by replacing antiquated, difficult, and cumbersome multi-part kits with simple, convenient, portable therapies."
In other words, the company is using the devices to deliver liquid glucagon for the treatment of hypoglycemia. (PR)